Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter

Iqvia stock bolted higher Monday after the contract research firm raised its outlook for the year on the back of unexpected strength.

Investors Business Daily

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Stocks With High Profit Margins

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

StockNews.com

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Investors Business Daily

Shanghai Composite Index Ended Nearly Flat on Friday

Shenzhen Component Index closed down 0.18%

Caixin Global

Read news from The Economist, FT, and more,
with one subscription

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street

Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.

Investors Business Daily

Lantheus Stock Gets A Radioactive Surge On Medicare Proposal

Lantheus stock rocketed to a record high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.

Investors Business Daily

The threat of litigation looms as Purdue Pharma returns to settlement talks

OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one

The Independent UK

South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate

The Independent UK

London biotech secures £90 million backing

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

Evening Standard

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices

Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.

Investors Business Daily

Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs

Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.

StockNews.com

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

International Business Times

US Supreme Court Rejects Opioid Settlement That Shields Sackler Family

The US Supreme Court on Thursday rejected Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family, which controlled the drugmaker, from future litigation.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Walgreens will close a ‘significant’ number of failing stores across US

There are 8,500 Walgreens stores across the country, and around a quarter are failing

The Conversation

Supreme Court rejects settlement with OxyContin maker Purdue Pharma over legal protections for the Sackler family that owned the company

The Supreme Court ruled 5-4 against an estimated US$6 billion Purdue Pharma bankruptcy plan on June 27, 2024, that would have shielded the Sackler family – which owned and controlled the company – from legal liability.

France 24

US Supreme Court rejects $6 billion OxyContin settlement shielding Sackler family

The US Supreme Court on Thursday rejected OxyContin maker Purdue Pharma's $6 billion settlement that would have shielded the Sackler family, who owned the company and earned tens of billions as it flooded the country with the highly addictive drug, from future civil lawsuits over the role they played in…

Investors Business Daily

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Investors Business Daily

Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection

Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.

The Independent UK

The legal odyssey for OxyContin maker Purdue Pharma and its owners is complex. Here's what to know

The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company

Investors Business Daily

Fluffy's Drugmaker Elanco Animal Health Plummets On Unexpected Safety Warning

Elanco stock plummeted Thursday after the company announced a pair of delays and a surprise warning for its new eczema treatment for dogs.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.